Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB25FQAKE
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,404
Award facts
- Contract value 100% obligated
- $3,404.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $3,404.32 to DMS Pharmaceutical Group Inc. for Xolair 300 mg/2 ml auto-injector vials on September 26, 2025, with an ultimate completion date of October 20, 2025. This firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's location in Park Ridge, Illinois. Xolair (omalizumab) is a monoclonal antibody medication used to treat moderate to severe allergic asthma and other allergic conditions, representing a specialized pharmaceutical product critical to military healthcare operations.
This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency valued at $499,999,999 through November 2026, which enables the agency to procure a comprehensive range of pharmaceutical products for Department of Defense healthcare facilities. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler that has established itself as a key supplier in the federal pharmaceutical supply chain through consistent performance delivering branded and generic prescription drugs, biologics, and medical consumables to military health facilities nationwide. The company's established relationship with the Defense Logistics Agency and extensive contract portfolio demonstrate its capability to reliably supply specialized pharmaceutical products supporting DoD healthcare requirements.
Quick answers
Who was awarded contract SPE2DB25FQAKE?
SPE2DB25FQAKE was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 26, 2025.
How much is contract SPE2DB25FQAKE worth?
The government has obligated $3,404 on SPE2DB25FQAKE.
Is contract SPE2DB25FQAKE an order under another contract?
Yes. SPE2DB25FQAKE is a delivery order under SPE2DB25D9305, an indefinite delivery contract.
Was contract SPE2DB25FQAKE competed?
The extent of competition for SPE2DB25FQAKE was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award